Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

From fork bombs to fake “language pack” removals, these commands can wreck Linux fast. Here’s what they do and how to stay ...

Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Leveraging modular gene editors and new regulatory pathways, Aurora will develop and commercialize therapies that can be rapidly tailored to many rare variants -- Founded by CRISPR pioneers Jennifer ...

Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...

Since the 2000s, Google Search—and later YouTube and Discover—served as the primary discovery and monetization engines for digital publishing. This relationship was symbiotic, if lopsided. Two decades ...

Former Google CEO Eric Schmidt believes AI's rapid advancement, already handling 10-20% of programming tasks, signals the end ...

Nkembuh, N. (2026) Symbiotic Communication Systems: Examining the Co-Evolution of Human-AI Communication Patterns in the ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...